Kintegral Advisory LLC Lowers Holdings in CME Group Inc. (NASDAQ:CME)

Kintegral Advisory LLC trimmed its position in CME Group Inc. (NASDAQ:CME - Free Report) by 32.9% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,427 shares of the financial services provider's stock after selling 2,662 shares during the quarter. Kintegral Advisory LLC's holdings in CME Group were worth $1,440,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in CME. Golden State Wealth Management LLC raised its stake in CME Group by 612.5% in the first quarter. Golden State Wealth Management LLC now owns 114 shares of the financial services provider's stock valued at $30,000 after buying an additional 98 shares during the last quarter. Alpine Bank Wealth Management acquired a new position in shares of CME Group in the first quarter valued at about $32,000. New Age Alpha Advisors LLC increased its holdings in shares of CME Group by 50.0% in the fourth quarter. New Age Alpha Advisors LLC now owns 129 shares of the financial services provider's stock valued at $30,000 after purchasing an additional 43 shares during the period. Knuff & Co LLC acquired a new position in shares of CME Group in the fourth quarter valued at about $33,000. Finally, Banque Transatlantique SA acquired a new position in shares of CME Group in the fourth quarter valued at about $35,000. 87.75% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently commented on CME. Bank of America raised their target price on CME Group from $200.00 to $219.00 and gave the stock an "underperform" rating in a report on Wednesday, April 2nd. Barclays raised their price objective on CME Group from $279.00 to $283.00 and gave the company an "equal weight" rating in a report on Wednesday, April 23rd. Erste Group Bank lowered CME Group from a "strong-buy" rating to a "hold" rating in a report on Saturday, May 24th. Morgan Stanley raised their price objective on CME Group from $301.00 to $304.00 and gave the company an "overweight" rating in a report on Thursday, April 24th. Finally, UBS Group raised their price objective on CME Group from $290.00 to $305.00 and gave the company a "buy" rating in a report on Friday, April 25th. Three equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $259.87.

CME Group Trading Down 0.4%

Shares of NASDAQ CME opened at $274.83 on Friday. CME Group Inc. has a twelve month low of $193.17 and a twelve month high of $290.79. The company has a current ratio of 1.02, a quick ratio of 1.02 and a debt-to-equity ratio of 0.13. The stock has a fifty day simple moving average of $276.40 and a 200-day simple moving average of $257.89. The stock has a market capitalization of $99.04 billion, a PE ratio of 27.65, a PEG ratio of 3.75 and a beta of 0.44.

CME Group (NASDAQ:CME - Get Free Report) last issued its quarterly earnings data on Wednesday, April 23rd. The financial services provider reported $2.80 earnings per share for the quarter, beating analysts' consensus estimates of $2.61 by $0.19. CME Group had a return on equity of 14.03% and a net margin of 57.71%. The business had revenue of $1.64 billion during the quarter, compared to analysts' expectations of $1.56 billion. During the same period in the previous year, the firm posted $2.50 earnings per share. The company's revenue was up 10.4% on a year-over-year basis. On average, equities analysts forecast that CME Group Inc. will post 10.49 earnings per share for the current year.

CME Group Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, June 25th. Stockholders of record on Monday, June 9th were paid a $1.25 dividend. The ex-dividend date was Monday, June 9th. This represents a $5.00 dividend on an annualized basis and a dividend yield of 1.82%. CME Group's payout ratio is presently 50.30%.

Insiders Place Their Bets

In other news, Director Charles P. Carey sold 500 shares of CME Group stock in a transaction on Tuesday, June 10th. The stock was sold at an average price of $265.35, for a total value of $132,675.00. Following the completion of the sale, the director directly owned 4,900 shares of the company's stock, valued at approximately $1,300,215. The trade was a 9.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director William R. Shepard bought 256 shares of the stock in a transaction that occurred on Wednesday, June 25th. The shares were bought at an average cost of $270.53 per share, with a total value of $69,255.68. Following the completion of the purchase, the director directly owned 258,196 shares in the company, valued at $69,849,763.88. This represents a 0.10% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders sold 13,400 shares of company stock valued at $3,680,610. Insiders own 0.30% of the company's stock.

About CME Group

CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.

Want to see what other hedge funds are holding CME? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CME Group Inc. (NASDAQ:CME - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.